Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
426c.Mod.Core-C4b Vaccine Adjuvanted With 3M-052-AF + Alum in Infants With Perinatal HIV Exposure
NCT06613789Phase 1Not yet recruiting
- Sponsor
- HIV Vaccine Trials Network
- Start
- Mar 2027
- Primary completion
- Jun 2027
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of 426c.Mod.Core-C4b in human immunodeficiency virus infection (HIV) (6 arms), sponsored by HIV Vaccine Trials Network. Primary endpoints: Number of participants reporting local reactogenicity signs and symptoms, Number of participants reporting systemic reactogenicity signs and symptoms and 7 more. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
426c.Mod.Core-C4b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06613789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613789.